# **List of Publications** Henriette Meyer zu Schwabedissen

**2024**

1. *Influence of Slco2b1-knockout and SLCO2B1-humanization on coproporphyrin I and III levels in rats.* Kinzi J, Hussner J, Schäfer AM, Treyer A, Seibert I, Tillmann A, Mueller V, Gherardi C, Vonwyl C, Hamburger M, Meyer Zu Schwabedissen HE. Br J Pharmacol. 2024; 181(1):36-53.
2. *St. John's wort formulations induce rat CYP3A23-3A1 independent of their hyperforin content.* Schäfer AM, Rysz MA, Schädeli J, Hübscher M, Khosravi H, Fehr M, Seibert I, Potterat O, Smieško M, Meyer Zu Schwabedissen HE. Molecular Pharmacology. 2024; 105(1):14-22.

**2023**

3. *Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service.* Jeiziner C, Meyer Zu Schwabedissen HE, Hersberger KE, Allemann SS. Int J Clin Pharm. 2023; 45(6):1378–1386.
4. *Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population.* Kirchner K, Garvert L, Wittfeld K, Ameling S, Bülow R, Meyer zu Schwabedissen H, Nauck M, Völzke H, Grabe HJ, Van der Auwera S. Int. J. Mol. Sci. 2023; 24(2):1120.
5. *Pharmacogenetic Analysis Enables Optimization of Pain Therapy: A Case Report of Ineffective Oxycodone Therapy.* Wiss FM, Stäuble CK, Meyer zu Schwabedissen HE, Allemann SS, Lampert ML. J. Pers. Med. 2023; 13(5):829.
6. *Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study.* Bollinger A, Stäuble CK, Jeiziner C, Wiss FM, Hersberger KE, Lampert ML, Meyer zu Schwabedissen HE, Allemann SS. Pharmgenomics Pers Med. 2023; 16:693-706.
7. *Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.* Rysz MA, Kinzi J, Schäfer AM, In-Albon K, Zürcher S, Schmidlin S, Seibert I, Schwardt O, Ricklin D, Meyer Zu Schwabedissen HE. J Pharm Biomed Anal. 2023; 236:115716.
8. *The influence of OATP2B1 and atorvastatin on coproporphyrin isomers in rats.* Kinzi J, Grube M, Hussner J, Seibert I, Hamburger M, Meyer Zu Schwabedissen HE. J Pharmacol Sci. 2023; 153(3):170-174.
9. *Various effects of repeated rifampin dosing on coproporphyrin levels in humans.* Kinzi J, Grube M, Brecht K, Seibert I, Siegmund W, Meyer Zu Schwabedissen HE. Clin Transl Sci. 2023; 16(11):2289–2298.
10. *Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report.* Bollinger A, Jeiziner C, Meyer Zu Schwabedissen HE, Hersberger KE, Allemann SS, Stäuble CK. Pharmacogenomics. 2023; 24(14):739–746.

**2022**

11. *Impact of the clinically approved Petasites hybridus extract Ze 339 on intestinal mechanisms involved in the handling of histamine.* Mettler LG, Brecht K, Butterweck V, Meyer zu Schwabedissen HE. Biomed Pharmacother. 2022; 148:112698
12. *Constituents of Passiflora incarnata, but Not of Valeriana officinalis, Interact with the Organic Anion Transporting Polypeptides (OATP)2B1 and OATP1A2.* Schäfer AM, Gilgen PM, Spirgi C, Potterat O, Meyer Zu Schwabedissen HE. Planta Med. 2022; 88(2):152-162.
13. *Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite* 4-methylaminoantipyrine. Bachmann F, Meyer Zu Schwabedissen HE, Duthaler U, Krähenbühl S. Br J Clin Pharmacol. 2022; 88(4):1885-1896.
14. Development of the Swiss Database for dosing medicinal products in pediatrics. Tilen R, Panis D, Aeschbacher S, Sabine T, Meyer zu Schwabedissen HE, Berger C. Eur J Pediatr. 2022; 181:1221–1231 (2022)
15. *A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting.* Stäuble, C. K., Jeiziner, C., Bollinger, A., Wiss, F. M., Hatzinger, M., Hersberger, K. E., Ihde, T., Lampert, M. L., Mikoteit, T., Meyer Zu Schwabedissen, H. E. and Allemann, S. S. Pharmacy. 2022; 10(4):86.
16. *Pharmacogenetic Analysis of Voriconazole Treatment in Children.* Tilen, R., Paioni, P., Goetschi, A. N., Goers, R., Seibert, I., Müller, D., Bielicki, J. A., Berger, C., Krämer, S. D. and Meyer Zu Schwabedissen, H. E. Pharmaceutics. 2022; 14(6):1289.
17. *Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.* Brouwer, K.L.R., Evers, R., Hayden, E., Hu, S., Li, C.Y., Meyer zu Schwabedissen, H.E., Neuhoff, S., Oswald, S., Piquette-Miller, M., Saran, C., Sjöstedt, N., Sprowl, J.A., Stahl, S.H. and Yue, W. Clinical pharmacology and therapeutics. 2022; 112(3):461–484.
18. *Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene.* Stäuble CK, Meier R, Lampert ML, Mikoteit T, Hatzinger M, Allemann SS, Hersberger KE and Meyer zu Schwabedissen HE. Front. Psychiatry. 2022; 13:942268.
19. *Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.* Huynh C, Seeland S, Segrestaa J, Gnerre C, Hogeback J, Meyer zu Schwabedissen HE, Dingemanse J and Sidharta PN. Front. Pharmacol. 2022; 13:812065
20. *Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report*. Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE. Pharmgenomics Pers Med. 2022;15:465-475
21. *Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta.* Taggi, V.; Riera Romo, M.; Piquette-Miller, M.; Meyer zu Schwabedissen, H.E.; Neuhoff, S. Pharmaceutics. 2022; 14(7):1376
22. *Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database.* Wittwer NL, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann S, Schneider C. Pharmgenomics Pers Med. 2022; 15:967-976

**2021**

23. *Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial*. Stäuble CK, Lampert ML, Allemann S, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE, Imboden C, Mikoteit T. Trials. 2021; 22(1):919.
24. *Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans.* Huynh C, Brussee JM, Pouzol L, Fonseca M, Meyer Zu Schwabedissen HE, Dingemanse J, Sidharta PN. Biomed Pharmacother. 2021;144:112363.
25. *SwissPK$^{cdw}$ - A clinical data warehouse for the optimization of pediatric dosing regimens.* Goers R, Coman Schmid D, Jäggi VF, Paioni P, Okoniewski MJ, Parker A, Bangerter B, Georgakopoulou S, Sengstag T, Bielicki J, Tilen R, Vermeul S, Krämer SD, Berger C, Rinn B, Meyer zu Schwabedissen HE. CPT Pharmacometrics Syst Pharmacol. 2021 (12):1578-1587
26. *Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1)*. Hussner J, Foletti A, Seibert I, Fuchs A, Schuler E, Malagnino V, Grube M, Meyer zu Schwabedissen HE. Drug Metab Pharmacokinet. 2021;41:100418
27. *Gentamicin Population Pharmacokinetics in Pediatric Patients-A Prospective Study with Data Analysis Using the saemix Package in R*. Paioni P, Jäggi VF, Tilen R, Seiler M, Baumann P, Bräm DS, Jetzer C, Haid RTU, Goetschi AN, Goers R, Müller D, Coman Schmid D, Meyer zu Schwabedissen HE, Rinn B, Berger C, Krämer SD. Pharmaceutics. 2021 Oct 1;13(10):1596.
28. *Pharmacogenetics in Pharmaceutical Care-Piloting an Application-Oriented Blended Learning Concept.* Stäuble CK, Jeiziner C, Hersberger KE, Meyer zu Schwabedissen HE, Lampert ML. Pharmacy (Basel). 2021 Sep 6;9(3):152.
29. *HLA-associated adverse drug reactions - scoping review.* Jeiziner C, Wernli U, Suter K, Hersberger KE, Meyer zu Schwabedissen HE. Clin Transl Sci. 2021; 14(5):1648-1658. Review
30. *Pharmacogenetic information in Swiss drug labels - a systematic analysis.* Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M, Klein TE, Szucs TD, Hersberger KE, Meyer zu Schwabedissen HE. Pharmacogenomics J. 2021; 21(4):423-434.
31. *Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report.* Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE. Life (Basel). 2021;11(7):673.
32. *Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.* Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE. Int J Mol Sci. 2021; 22(12):6480.
33. *Expression and Function of Organic Anion Transporting Polypeptides in the Human Brain: Physiological and Pharmacological Implications*. Schäfer AM, Meyer zu Schwabedissen HE, Grube M. Pharmaceutics. **2021**;13(6):834. Review
34. *OATP2B1 - The underrated member of the organic anion transporting polypeptide family of drug transporters?* Kinzi J, Grube M, Meyer zu Schwabedissen HE. Biochem Pharmacol. **2021**;188:114534. Review
35. *A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.* Huynh C, Henrich A, Strasser DS, Boof ML, Al-Ibrahim M, Meyer zu Schwabedissen HE, Dingemanse J, Ufer M. Clin Pharmacol Ther. 2021; 109(6):1648-1659
36. *Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2.* Bachmann F, Duthaler U, Meyer zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, Krähenbühl S. Clin Pharmacol Ther. 2021; 109(6):1505-1516

37. *Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions.* Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE, Pharmgenomics Pers Med. 2021;14:279-286
38. *Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR-) Rats.* Bezençon J, Saran C, Hussner J, Beaudoin JJ, Zhang Y, Shen H, Fallon JK, Smith PC, Meyer zu Schwabedissen HE, Brouwer KLR. J Pharm Sci. 2021;110(1):404-411.

**2020**

39. *Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders.* Bonk S, Hertel J, Zacharias HU, Terock J, Janowitz D, Homuth G, Nauck M, Völzke H, Meyer zu Schwabedissen H, Van der Auwera S, Grabe HJ. Sci Rep. 2020;10(1):22394.
40. *Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report.* Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE. Pharmacogenomics. 2020;21(16):1145-1150.
41. *Genetic variants of SLCO1B7 are of relevance for the transport function of OATP1B3-1B7.* Meyer Zu Schwabedissen HE, Seibert I, Grube M, Alter CL, Siegmund W, Hussner J. Pharmacol Res. 2020;161:105155.
42. *Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics?* Brecht K, Schäfer AM, Meyer zu Schwabedissen HE. Cancers (Basel). **2020**;12(8):2263. Review
43. *Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions*. Huynh C, Dingemanse J, Meyer zu Schwabedissen HE, Sidharta PN. Pharmacol Res. **2020**; 161:105092. Review
44. *OATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor Agonists and Antagonists.* Schäfer AM, Meyer zu Schwabedissen HE, Bien-Möller S, Hubeny A, Vogelgesang S, Oswald S, Grube M. Mol Pharm. 2020;17(6):1987-1995.
45. *Design, Synthesis, and Characterization of a Paclitaxel Formulation Activated by Extracellular MMP9.* Ehrsam D, Sieber S, Oufir M, Porta F, Hamburger M, Huwyler J, Meyer zu Schwabedissen HE. Bioconjug Chem. 2020;31(3):781-793.
46. *Clinical relevance of St. John's wort drug interactions revisited.* Nicolussi S, Drewe J, Butterweck V, Meyer zu Schwabedissen HE. Br J Pharmacol. **2020;**177(6):1212-1226. Review

**2019**

*47. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.* Malagnino V, Hussner J, Issa A, Midzic A, Meyer zu Schwabedissen HE. Am J Physiol Gastrointest Liver Physiol. 2019;317(6):G751-G762.

48. *PDMS-PMOXA-Nanoparticles Featuring a Cathepsin B-Triggered Release Mechanism.* Ehrsam D, Porta F, Hussner J, Seibert I, Meyer zu Schwabedissen HE. Materials. 2019;12(17):2836.

*49. Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.* Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Schöneweis K, Grossen P, Buck J, Ni Y, Schenk SH, Hussner J, Meyer zu Schwabedissen HE, Québatte G, Mier W, Urban S, Huwyler J. Elife. 2019 8. pii: e42276. doi: 10.7554/eLife.42276.

*50. OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe.* Malagnino V, Duthaler U, Seibert I, Krähenbühl S, Meyer zu Schwabedissen HE. Mol Pharmacol. 2019;96(2):128-137.

*51. Unravelling the Antiproliferative Activity of 1,2,5-oxadiazole Derivatives* Ehrsam D, Porta F, Mori M, Meyer zu Schwabedissen HE, Dalla Via L, Garcia-Argaez AN, Basile L, Meneghetti F, Villa S, Gelain A. Anticancer Res. 2019;39(7):3453-3461.

52. *Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects.* Vizeli P, Meyer zu Schwabedissen HE, Liechti ME. ACS Chem Neurosci. 2019;10(7):3120-3131
53. *The nuclear receptors PXR and LXR are regulators of the scaffold protein PDZK1.* Ferreira C, Meyer R, Meyer zu Schwabedissen HE. Biochim Biophys Acta Gene Regul Mech. 2019;1862(4):447-456
54. *Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.* Leuppi-Taegtmeyer A, Duthaler U, Hammann F, Schmid Y, Dickenmann M, Amico P, Jehle AW, Kalbermatter S, Lenherr C, Meyer zu Schwabedissen HE, Haschke M, Liechti ME, Krähenbühl S. Nephrol Dial Transplant. 2019;34(4):692-702
55. *Hyperforin induced activation of the Pregnane X Receptor is influenced by the Organic Anion Transporting Polypeptide 2B1 (OATP2B1).* Schaefer AM, Potterat O, Seibert I, Fertig O, Meyer zu Schwabedissen HE. Mol Pharmacol. 2019;95(3):313-323.
56. *Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.* Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Meyer zu Schwabedissen HE, Krähenbühl S, Hammann F. Br J Clin Pharmacol. 2019;85(3):626-633.

**2018**

57. *Establishment and Validation of Competitive Counterflow as a Method to Detect Substrates of the Organic Anion Transporting Polypeptide 2B1.*Schäfer AM, Bock T, Meyer zu Schwabedissen HE. Mol Pharm. 2018; 15(12):5501-5513
58. *Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer.* Porta F, Ehrsam D, Lengerke C, Meyer zu Schwabedissen HE. Mol Pharm. 2018; 15(11):4884-4897
59. *Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation*. Teumer A, Chaker L, Groeneweg S, Li Y, Di Munno C, Barbieri C, Schultheiss UT, Traglia M, Ahluwalia TS, Akiyama M, Appel EVR, Arking DE, Arnold A, Astrup A, Beekman M, Beilby JP, Bekaert S, Boerwinkle E, Brown SJ, De Buyzere M, Campbell PJ, Ceresini G, Cerqueira C, Cucca F, Deary IJ, Deelen J, Eckardt KU, Ekici AB, Eriksson JG, Ferrrucci L, Fiers T, Fiorillo E, Ford I, Fox CS, Fuchsberger C, Galesloot TE, Gieger C, Gögele M, De Grandi A, Grarup N, Greiser KH, Haljas K, Hansen T, Harris SE, van Heemst D, den Heijer M, Hicks AA, den Hollander W, Homuth G, Hui J, Ikram MA, Ittermann T, Jensen RA, Jing J, Jukema JW, Kajantie E, Kamatani Y, Kasbohm E, Kaufman JM, Kiemeney LA, Kloppenburg M, Kronenberg F, Kubo M, Lahti J, Lapauw B, Li S, Liewald DCM; Lifelines Cohort Study, Lim EM, Linneberg A, Marina M, Mascalzoni D, Matsuda K, Medenwald D, Meisinger C, Meulenbelt I, De Meyer T, Meyer zu Schwabedissen HE, Mikolajczyk R, Moed M, Netea-Maier RT, Nolte IM, Okada Y, Pala M, Pattaro C, Pedersen O, Petersmann A, Porcu E, Postmus I, Pramstaller PP, Psaty BM, Ramos YFM, Rawal R, Redmond P, Richards JB, Rietzschel ER, Rivadeneira F, Roef G, Rotter JI, Sala CF, Schlessinger D, Selvin E, Slagboom PE, Soranzo N, Sørensen TIA, Spector TD, Starr JM, Stott DJ, Taes Y, Taliun D, Tanaka T, Thuesen B, Tiller D, Toniolo D, Uitterlinden AG, Visser WE, Walsh JP, Wilson SG, Wolffenbuttel BHR, Yang Q, Zheng HF, Cappola A, Peeters RP, Naitza S, Völzke H, Sanna S, Köttgen A, Visser TJ, Medici M. Nat Commun. 2018*;* 9(1):4455.
60. *Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression*. Cluverhouse RC et al. Mol Psychiatry. 2018; 23(1):133-142.
61. *The scaffold protein PDZK1 modulates expression and function of the organic anion transporting polypeptide 2B1.* Ferreira C, Hagen P, Stern M, Hussner J, Zimmermann U, Grube M, Meyer zu Schwabedissen HE. Eur J Pharm Sci. 2018;120:181-190

62. *Thyroid hormones are transport substrates and transcriptional regulators of Organic Anion Transporting Polypeptide 2B1.* Meyer zu Schwabedissen HE, Ferreira C, Schaefer AM, Oufir M, Seibert I, Hamburger M, Tirona RG. Mol Pharmacol. 2018; 94(1):700-712
63. *No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA*. Vizeli P, Meyer zu Schwabedissen HE, Liechti ME. Eur J Clin Pharmacol. 2018; 74(3):275-283
64. *PDZ domain containing protein 1 (PDZK1), a modulator of membrane proteins, is regulated by the nuclear receptor THRβ.* Ferreira C, Prestin K, Hussner J, Zimmermann U, Meyer zu Schwabedissen HE. Mol Cell Endocrinol. 2018; 461:215-225.
65. *LST-3TM12 is a member of the OATP1B family and a functional transporter.* Malagnino V, Hussner J, Seibert I, Stolzenburg A, Sager CP, Meyer Zu Schwabedissen HE. Biochem Pharmacol. 2018; 148:75-87.
66. *Childhood Trauma and Functional Variants of 5-HTTLPR Are Independently Associated with Alexithymia in 5,283 Subjects from the General Population.* Terock J, Van der Auwera S, Janowitz D, Homuth G, Hannemann A, Schmidt CO, Meyer Zu Schwabedissen H, Freyberger HJ, Grabe HJ. Psychother Psychosom. 2018; 87(1):58-61

**2017**

67. *Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).* Prestin K, Olbert M, Hussner J, Völzke H, Meyer zu Schwabedissen HE. Pharmacogenet Genomics. 2017; 27(11):410-415.
68. *Doxorubicin enhances oxysterol levels resulting in a LXR-mediated upregulation of cardiac cholesterol transporters*. Monzel JV, Budde T, Meyer zu Schwabedissen HE, Schwebe M, Bien-Möller S, Lütjohann D, Kroemer HK, Jedlitschky G, Grube M. Biochem Pharmacol. 2017; 144:108-119.
69. *Regulation of PDZ domain containing 1 (PDZK1) Expression by Hepatocyte Nuclear Factor 1 alpha (HNF1α) in Human Kidney*. Prestin K, Hussner J, Ferreira C, Seibert I, Breitung V, Zimmermann U, Meyer Zu Schwabedissen HE. Am J Physiol Renal Physiol. 2017; 313(4): F973-F983.
70. *Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas*. Kim M, Deacon P, Tirona RG, Kim RB, Pin CL, Meyer zu Schwabedissen HE, Wang R, Schwarz UI. Histochem Cell Biol. 2017; 148(4): 345-357.
71. *Biocorona: The Shadowed Side of Nanoparticles*. Porta F, Ehrsam DS, Meyer zu Schwabedissen HE Modern Applications of Bioequivalence and Bioavailability **2017** 2(3) 001- 003. Review
72. *Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects*. Vizeli P, Schmid Y, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. Eur Neuropsychopharmacology 2017;27(3):232-238.
73. *Genetic loci associated with heart rate variability and their effects on cardiac disease risk*. Nolte IM et al. Nature Communications 2017; 8:15805.

**2016**

74. *Modulation of Expression of the Nuclear Receptor NR0B2 (Small Heterodimer Partner 1 SHP1) and its Impact on Cell Proliferation of Renal Carcinoma Cells*. Prestin K, Olbert M, Hussner J, Isenegger T, Gliesche DG, Böttcher K, Zimmermann U, Meyer zu Schwabedissen HE. OncoTargets and Therapy. 2016; 9:4867-4878.
75. *CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.* Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. Pharmacogenetics Genomics. 2016; 26(8):397-401.
76. *Secreted Matrix Metalloproteinase-9 of proliferating smooth muscle cells as a trigger for drug release from stent surface polymers in coronary arteries.* Gliesche DG, Hussner J, Witzigmann D, Porta F, Glatter

T, Schmidt A, Huwyler J, Meyer zu Schwabedissen HE. Molecular Pharmaceutics. 2016; 13(7):2290-2300.

77. *Pimecrolimus increases the expression of interferon-inducible genes that modulate human coronary artery cells proliferation.* Hussner J, Sünwoldt J, Seibert I, Gliesche DG, Meyer zu Schwabedissen HE. European Journal of Pharmacology. 2016; 784:137-146.
78. *Effect of the interaction between childhood abuse and rs1360780 of the FKBP5 gene on gray matter volume in a general population sample*. Grabe HJ, Wittfeld K, Van der Auwera S, Janowitz D, Hegenscheid K, Habes M, Homuth G, Barnow S, John U, Nauck M, Völzke H, Meyer zu Schwabedissen H, Freyberger HJ, Hosten N. Human Brain Mapping. 2016; 37(4):1602-13.
79. *Tailored surface design of biodegradable endovascular implants by functionalization of poly (L-lactide) with elastin-like proteins.* Petersen S, Gliesche DG, Kurtbay G, Begunk R, Boeck M, Hopf V, Kroemer HK, Schmitz KP, Meyer zu Schwabedissen HE, Sternberg K. Journal of Biomedical Engeneering and Informatics 2016; 2(1):52-64.

**2015**

80. *The Pim1 kinase is up-regulated in Glioblastoma multiforme and mediates tumor cell survival.* Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, Miletic H, Hildner M, Fritsch M, Vogelgesang S, Havemann C, Ritter CA, Meyer zu Schwabedissen HE, Rauch BH, Hoffmann W, Kroemer HK, Schroeder H, Bien-Möller S. Journal of Neuro-Oncology. 2015; 17(2):223-42.
81. *Function impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify therapeutic efficacy of statins in a population based cohort.* Meyer zu Schwabedissen HE, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H, Siegmund W, Völzke H, Kroemer HK. Pharmacogenetics and Genomics 2015; 25(1):8-18.
82. *Expression of OATP2B1 as determinant of drug effects in the microcompartment of the coronary artery*. Hussner J, Begunk R, Boettcher K, Gliesche DG, Prestin K, Meyer zu Schwabedissen HE. Vascular Pharmacology. 2015; 72:25-34.

**2014**

83. *Interaction among childhood trauma and functional polymorphisms in the serotonin pathway moderate the risk of depressive disorders*. Van der Auwera S, Janowitz D, Schulz A, Homuth G, Nauck M, Völzke H, Rose M, Meyer zu Schwabedissen H, Freyberger HJ, Grabe HJ. European Archives of Psychiatry and Clinical Neuroscience. 2014; 264 Suppl 1:S45-54.
84. *Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.* Meyer zu Schwabedissen HE, Siegmund W, Kroemer HK, Rollnik JD. BMC Research Notes. 2014; 7:688.
85. *Transcriptional Regulation of the Urate Transportosome Member SLC2A9 by Nuclear Receptor HNF4α.* Hentschel K, Wolf S, Feldtmann R, Hussner J, Geissler I, Rimmbach C, Zimmermann U, Meyer zu Schwabedissen HE. American Journal of Physiology - Renal Physiology. 2014; 307(9): F1041-51.
86. *Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease.* Medici M, Porcu E, Pistis G, Teumer A, Brown SJ, Jensen RA, Rawal R, Roef GL, Plantinga TS, Vermeulen SH, Lahti J, Simmonds MJ, Husemoen LL, Freathy RM, Shields BM, Pietzner D, Nagy R, Broer L, Chaker L, Korevaar TI, Plia MG, Sala C, Völker U, Richards JB, Sweep FC, Gieger C, Corre T, Kajantie E, Thuesen B, Taes YE, Visser WE, Hattersley AT, Kratzsch J, Hamilton A, Li W, Homuth G, Lobina M, Mariotti S, Soranzo N, Cocca M, Nauck M, Spielhagen C, Ross A, Arnold A, van de Bunt M, Liyanarachchi S, Heier M, Grabe HJ, Masciullo C, Galesloot TE, Lim EM, Reischl E, Leedman PJ, Lai S, Delitala A, Bremner AP, Philips DI, Beilby JP, Mulas A, Vocale M, Abecasis G, Forsen T, James

A, Widen E, Hui J, Prokisch H, Rietzschel EE, Palotie A, Feddema P, Fletcher SJ, Schramm K, Rotter JI, Kluttig A, Radke D, Traglia M, Surdulescu GL, He H, Franklyn JA, Tiller D, Vaidya B, de Meyer T, Jørgensen T, Eriksson JG, O'Leary PC, Wichmann E, Hermus AR, Psaty BM, Ittermann T, Hofman A, Bosi E, Schlessinger D, Wallaschofski H, Pirastu N, Aulchenko YS, de la Chapelle A, Netea-Maier RT, Gough SC, Meyer Zu Schwabedissen HE, Frayling TM, Kaufman JM, Linneberg A, Räikkönen K, Smit JW, Kiemeney LA, Rivadeneira F, Uitterlinden AG, Walsh JP, Meisinger C, den Heijer M, Visser TJ, Spector TD, Wilson SG, Völzke H, Cappola A, Toniolo D, Sanna S, Naitza S, Peeters RP. PLoS Genetics. 2014; 10(2).

87. *Cohort profile: Greifswald Approach to Individualized Medicine (GANI_MED).* Grabe HJ, Assel H, Bahls T, Dörr M, Endlich K, Endlich N, Erdmann P, Ewert R, Felix S, Fiene B, Fischer T, Flessa S, Nele Friedrich N, Gadebusch-Bondio M, Gesell Salazar M, Hammer E, Haring R, Havemann C, Hecker M, Hoffmann W, Holtfreter B, Kacprowski T, Klein K, Kocher T, Kock H, Krafczyk J, Kuhn J, Langanke M, Lendeckel U, Lerch MM, Lieb W, Lorbeer R, Mayerle J, Meissner K, Meyer zu Schwabedissen HE, Nauck M, Ott K, Rathmann W, Rettig R, Richardt C, Saljé K, Schminke U, Schulz A, Schwab M, Siegmund W, Stracke S, Suhre K, Ueffing M, Ungerer S, Völker U, Völzke H, Wallaschofski H, Werner V, Zygmunt MT and Kroemer HK. Journal of Translational Medicine. 2014; 12:144
88. *Multimodal imaging of a tescalcin (TESC)-regulating polymorphism (rs7294919)-specific effects on hippocampal gray matter structure.* Dannlowski U, Grabe HJ, Wittfeld K, Klaus J, Konrad C, Grotegerd D, Redlich R, Suslow T, Opel N, Ohrmann P, Bauer J, Zwanzger P, Laeger I, Hohoff C, Arolt V, Heindel W, Deppe M, Domschke K, Hegenscheid K, Völzke H, Stacey D, Meyer zu Schwabedissen H, Kugel H, Baune BT. Molecular Psychiatry. 2014; 20(3):398-404.
89. *Cell-Specific Expression of Uptake Transporters-A Potential Approach for Cardiovascular Drug Delivery Devices*. Meyer zu Schwabedissen HE, Begunk R, Hussner J, Juhnke BO, Gliesche D, Böttcher K, Sternberg K, Schmitz KP, Kroemer HK. Molecular Pharmaceutics. 2014; 11(3):665-72.
90. *Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization*. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia N, Rossin EJ, Morley M, Wang X, Johnson AD, Lundby A, Gudbjartsson DF, Noseworthy PA, Eijgelsheim M, Bradford Y, Tarasov KV, Dörr M, Müller-Nurasyid M, Lahtinen AM, Nolte IM, Smith AV, Bis JC, Isaacs A, Newhouse SJ, Evans DS, Post WS, Waggott D, Lyytikäinen LP, Hicks AA, Eisele L, Ellinghaus D, Hayward C, Navarro P, Ulivi S, Tanaka T, Tester DJ, Chatel S, Gustafsson S, Kumari M, Morris RW, Naluai AT, Padmanabhan S, Kluttig A, Strohmer B, Panayiotou AG, Torres M, Knoflach M, Hubacek JA, Slowikowski K, Raychaudhuri S, Kumar RD, Harris TB, Launer LJ, Shuldiner AR, Alonso A, Bader JS, Ehret G, Huang H, Kao WH, Strait JB, Macfarlane PW, Brown M, Caulfield MJ, Samani NJ, Kronenberg F, Willeit J; CARe Consortium; COGENT Consortium, Smith JG, Greiser KH, Meyer zu Schwabedissen H, Werdan K, Carella M, Zelante L, Heckbert SR, Psaty BM, Rotter JI, Kolcic I, Polašek O, Wright AF, Griffin M, Daly MJ; DCCT/EDIC, Arnar DO, Hólm H, Thorsteinsdottir U; eMERGE Consortium, Denny JC, Roden DM, Zuvich RL, Emilsson V, Plump AS, Larson MG, O'Donnell CJ, Yin X, Bobbo M, D'Adamo AP, Iorio A, Sinagra G, Carracedo A, Cummings SR, Nalls MA, Jula A, Kontula KK, Marjamaa A, Oikarinen L, Perola M, Porthan K, Erbel R, Hoffmann P, Jöckel KH, Kälsch H, Nöthen MM; HRGEN Consortium, den Hoed M, Loos RJ, Thelle DS, Gieger C, Meitinger T, Perz S, Peters A, Prucha H, Sinner MF, Waldenberger M, de Boer RA, Franke L, van der Vleuten PA, Beckmann BM, Martens E, Bardai A, Hofman N, Wilde AA, Behr ER, Dalageorgou C, Giudicessi JR, Medeiros-Domingo A, Barc J, Kyndt F, Probst V, Ghidoni A, Insolia R, Hamilton RM, Scherer SW, Brandimarto J, Margulies K, Moravec CE, Fabiola, Fuchsberger C, O'Connell JR, Lee WK, Watt GC, Campbell H, Wild SH, El Mokhtari NE, Frey N, Asselbergs FW, Leach IM, Navis G, van den Berg MP, van Veldhuisen DJ, Kellis M, Krijthe BP, Franco OH, Hofman A, Kors JA, Uitterlinden AG, Witteman JC, Kedenko L, Lamina C, Oostra BA, Abecasis GR, Lakatta EG, Mulas A, Orrú M, Schlessinger D, Uda

M, Markus MR, Völker U, Snieder H, Spector TD, Arnlöv J, Lind L, Sundström J, Syvänen AC, Kivimaki M, Kähönen M, Mononen N, Raitakari OT, Viikari JS, Adamkova V, Kiechl S, Brion M, Nicolaides AN, Paulweber B, Haerting J, Dominiczak AF, Nyberg F, Whincup PH, Hingorani AD, Schott JJ, Bezzina CR, Ingelsson E, Ferrucci L, Gasparini P, Wilson JF, Rudan I, Franke A, Mühleisen TW, Pramstaller PP, Lehtimäki TJ, Paterson AD, Parsa A, Liu Y, van Duijn CM, Siscovick DS, Gudnason V, Jamshidi Y, Salomaa V, Felix SB, Sanna S, Ritchie MD, Stricker BH, Stefansson K, Boyer LA, Cappola TP, Olsen JV, Lage K, Schwartz PJ, Kääb S, Chakravarti A, Ackerman MJ, Pfeufer A, de Bakker PI, Newton-Cheh C. Nature Genetics. 2014*;* 46(8):826-36.

91. *OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.* Meyer Zu Schwabedissen HE, Boettcher K, Steiner T, Schwarz UI, Keiser M, Kroemer HK, Siegmund W. Diabetes*.* 2014; 63(2):775-84.
92. *Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality.* Haring R, Friedrich N, Völzke H, Vasan RS, Felix SB, Dörr M, Meyer zu Schwabedissen HE, Nauck M, Wallaschofski H. European Heart Journal. 2014; 35(18):1215-21.

**2013**

93. *In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.* Petersen S, Hussner J, Reske T, Grabow N, Senz V, Begunk R, Arbeiter D, Kroemer HK, Schmitz KP, Meyer zu Schwabedissen HE, Sternberg K. Journal of Materials Science Materials in Medicine. 2013; 24(11).
94. *Personalized cardiovascular medicine: concepts and methodological considerations.* Völzke H, Schmidt CO, Baumeister SE, Ittermann T, Fung G, Krafczyk-Korth J, Hoffmann W, Schwab M, Meyer zu Schwabedissen HE, Dörr M, Felix SB, Lieb W, Kroemer HK. Nature Reviews Cardiology. **2013**; 10(6):308-16. Review
95. *Implant-associated local drug delivery systems based on biodegradable polymers: customized designs for different medical applications.* Sternberg K, Petersen S, Grabow N, Senz V, Meyer zu Schwabedissen HE, Kroemer HK, Schmitz KP. Biomedizinische Technik (Berl). **2013**; 58(5):417-27. Review
96. *Heparin inhibits TNF-α signaling in human endometrial stromal cells by interaction with NF-κB.* Spratte J, Meyer Zu Schwabedissen H, Endlich N, Zygmunt M, Fluhr H. Molecular Human Reproduction. 2013; 19(4):227-36.

**2012**

97. *Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy.* Riad A, Meyer zu Schwabedissen H, Weitmann K, Herda LR, Dörr M, Empen K, Kieback A, Hummel A, Reinthaler M, Grube M, Klingel K, Nauck M, Kandolf R, Hoffmann W, Kroemer HK, Felix SB. Journal of Biological Chemistry. 2012; 287(32):27236-43.
98. *Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo.* Meyer Zu Schwabedissen HE, Oswald S, Bresser C, Nassif A, Modess C, Desta Z, Ogburn ET, Marinova M, Lütjohann D, Spielhagen C, Nauck M, Kroemer HK, Siegmund W. Clinical Pharmacology and Therapeutics. 2012; 92(1):103-11.
99. *Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function*. Rawal R, Teumer A, Völzke H, Wallaschofski H, Ittermann T, Asvold BO, Bjøro T, Greiser KH, Tiller D, Werdan K, Meyer Zu Schwabedissen HE, Doering A, Illig T, Gieger C, Meisinger C, Homuth G. Human Molecular Genetics. 2012; 21(14):3275-82.
100. *Inverse association between serum free thyroxine levels and hepatic steatosis: results from the study of health in pomerania.* Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M, Lerch M, Meyer zu Schwabedissen HE, Rosskopf D, Völzke H. Thyroid. 2012; 22(6):568-74.

101. *The effect of catechol-O-methyltransferase polymorphisms on pain is modified by depressive symptoms.* Schwahn C, Grabe HJ, Meyer zu Schwabedissen H, Teumer A, Schmidt CO, Brinkman C, Kocher T, Nauck M, Völzke H, Biffar R, Bernhardt O. European Journal of Pain. 2012; 16(6):878-89.
102. *Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.* Oswald S, Meyer zu Schwabedissen HE, Nassif A, Modess C, Desta Z, Ogburn ET, Mostertz J, Keiser M, Jia J, Hubeny A, Ulrich A, Runge D, Marinova M, Lütjohann D, Kroemer HK, Siegmund W. Clinical Pharmacology and Therapeutics. 2012; 91(3):506-13.
103. *In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna.* Cutler MJ, Urquhart BL, Velenosi TJ, Meyer zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ. Journal of Clinical Pharmacology. 2012; 52(4):530-42.

**2011**

104. *Current understanding of hepatic OATP-mediated drug–drug interactions.* Koenen A., Kroemer HK, Grube M, Meyer zu Schwabedissen HE. Expert Reviews in Clinical Pharmacology. **2011**; 4(6):729-42. Review
105. *Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.* Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB. Pharmacogenetics and Genomics. 2011; 21(3):103-14. *Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.* Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Paré G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M, Smith NL, Smith AV, Sundvall J, Scheet P, Liu Y, Ruokonen A, Rose LM, Larson MG, Hoogeveen RC, Freimer NB, Teumer A, Tracy RP, Launer LJ, Buring JE, Yamamoto JF, Folsom AR, Sijbrands EJ, Pankow J, Elliott P, Keaney JF, Sun W, Sarin AP, Fontes JD, Badola S, Astor BC, Hofman A, Pouta A, Werdan K, Greiser KH, Kuss O, Meyer zu Schwabedissen HE, Thiery J, Jamshidi Y, Nolte IM, Soranzo N, Spector TD, Völzke H, Parker AN, Aspelund T, Bates D, Young L, Tsui K, Siscovick DS, Guo X, Rotter JI, Uda M, Schlessinger D, Rudan I, Hicks AA, Penninx BW, Thorand B, Gieger C, Coresh J, Willemsen G, Harris TB, Uitterlinden AG, Järvelin MR, Rice K, Radke D, Salomaa V, Willems van Dijk K, Boerwinkle E, Vasan RS, Ferrucci L, Gibson QD, Bandinelli S, Snieder H, Boomsma DI, Xiao X, Campbell H, Hayward C, Pramstaller PP, van Duijn CM, Peltonen L, Psaty BM, Gudnason V, Ridker PM, Homuth G, Koenig W, Ballantyne CM, Witteman JC, Benjamin EJ, Perola M, Chasman DI. Circulation. 2011; 123(7):731-8.
106. *Hepatic OATP Transporter and Thyroid Hormone Receptor Interplay Determines Cholesterol and Glucose Homeostasis*. Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry A, Lemay S, Leon-Ponte M, Strom SC, Zaher H, Schwarz UI, Freeman DJ, Schuetz EG, Tirona RG and Kim RB. Hepatology. 2011; 54(2):644-54.
107. *Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians.* Stickel F, Buch S, Lau K, Meyer zu Schwabedissen HE, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe J. Hepatology. 2011; 53(1):86-95.

**2010**

108. *A piece in the puzzle of personalized medicine.* Kroemer HK; Meyer zu Schwabedissen HE. Clinical Pharmacology and Therapeutics. **2010**; 87(1):19-20, Invited Commentary.

109. *Pharmacogenomics in Routine Medical Care.* Rosskopf D, Meyer zu Schwabedissen HE, Kroemer HK Siegmund W. Deutsche Medizinische Wochenschrift. **2010**; 135(4):133-44. Review
110. *LXRα (NR1H3) and FXR (NR1H4) are the major transcriptional regulators of OATP1B1*. Meyer zu Schwabedissen HE, Boettcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB. Hepatology. 2010; 52(5):1797-807.
111. *Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.* Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. American Journal of Physiology – Renal Physiology. 2010; 298(4):F997-F1005.
112. *Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins.* Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke C, Leake B, Kim RB, Tirona RG. Circulation Research. 2010; 106(2):297-306.
113. *Polymorphic Variants of the human Bile Salt Export Pump (BSEP, ABCB11): Functional Characterization and Interindividual Variability*. Ho RH, Leake BF, Kilkenny DM, Meyer zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB. Pharmacogenetics and Genomics. 2010; 20(1):45-57.

**2009**

114. *Hepatic OATP1B Transporters and Nuclear Receptors PXR and CAR:* Interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Meyer zu Schwabedissen HE, Kim RB. Molecular Pharmaceutics. **2009**; 6(6):1644-61. Review
115. *Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.* Meyer zu Schwabedissen HE, Ware JA, Tirona RG and Kim RB. Molecular Pharmaceutics. 2009; 6(6):1790-7.

**2008**

116. *Interplay between the Nuclear Receptor Pregnane X Receptor and the Uptake Transporter Organic Anion Transporter Polypeptide 1A2 Selectively Enhances Estrogen Effects in Breast Cancer.* Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. Cancer Research. 2008; 68(22):9338-47.
117. *Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin*. Zaher H†, Meyer zu Schwabedissen HE†, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA; † contributed equally. Molecular Pharmacology. 2008; 74(2):320-9.

**2007**

118. *Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type cGMP export pump*. Meissner K, Kessler W, Meyer zu Schwabedissen HE, Schuster K, Saalfeld K, Grube M, Buck A, Jedlitschky G, Maier S, Traeger T, Mostertz J, Homuth G, Heidecke CD, Lehmann C, Kroemer HK. Shock. 2007; 28(5):564-9.
119. *Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta*. Grube M, Reuther S, Meyer zu Schwabedissen HE, Köck K, Draber K, Ritter CA, Fusch C, Jedlitschky G, Kroemer HK. Drug Metabolism and Disposition. 2007; 35(1):30-5.

**2006**

120. *Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).* Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D, Eckel L, Bohm M, Jedlitschky G, Kroemer HK. Circulation. 2006; 113(8):1114-22.
121. *Epidermal Growth Factor (EGF) mediated activation of the MAP Kinase cascade results in altered expression and function of ABCG2 (BCRP).* Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter C.A, Völker U, Kroemer HK. Drug Metabolism and Disposition. 2006; 34(4):524-33.
122. *Direct Mass Spectrometric Identification of ABCB1 (P-glycoprotein/MDR1) from the Apical Membrane Fraction of Human Placenta using Fourier Transform Ion Cyclotron Mass Spectrometry (FTICR-MS).* Meyer zu Schwabedissen HE†, Dreisbach A†, Hammer E, Fusch C, Hecker M, Völker U, Kroemer HK; † contributed equally. Pharmacogenetics and Genomics. 2006; 16(6):385-9.
123. *The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, is Expressed in Human Heart.* Meissner K, Heydrich B, Jedlitschky G, Meyer zu Schwabedissen HE, Mosyagin I, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, Cascorbi I, Kroemer HK. Journal of Histochemistry and Cytochemistry. 2006; 54(2):215-21.

**2005**

124. *Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation.* Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. Drug Metabolism and Disposition. 2005; 33(7):896-904
125. *Expression, Localization, and Function of MRP5 (ABCC5), a Transporter for Cyclic Nucleotides in Human Placenta and Cultured Human Trophoblasts – Effects of Gestational Age and Cellular Differentiation.* Meyer zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, Jedlitschky G. American Journal of Pathology. 2005; 166(1):1-10.
126. *Expression, Localization and function of the Carnitine Transporter OCTN2 (SLC22A5) in human Placenta.* Grube M, Meyer zu Schwabedissen HE, Draber K, Prager D, Möritz KU, Linnemann K, Fusch C, Jedlitschky G, Kroemer HK. Drug Metabolism and Disposition. 2005; 33:1-7. *Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5).* Ritter CA, Jedlitschky G, Meyer zu Schwabedissen HE, Grube M, Köck K, Kroemer HK. Drug Metabolism Reviews. **2005**; 37(1):253-78. Review

**2004**

127. *Ezetimibe.* Meyer zu Schwabedissen HE, Kroemer HK. Deutsche Medizinische Wochenschrift. **2004;** 129(39):2038-40. Review
128. *Modulation of multidrug resistance protein 1 P-glycoprotein (ABCB1) expression in human heart by hereditary polymorphisms.* Meissner K, Jedlitschky G, Meyer zu Schwabedissen HE, Dazert P, Eckel L, Vogelgesang S, Warzok R, Bohm M, Lehmann C, Wendt M, Cascorbi I, Kroemer HK. Pharmacogenetics. 2004; 14(6):381-5.

**2002**

129. *Expression and Localization of P-Glycoprotein in Human Heart: Effects of Cardiomyopathy.* Meissner K, Sperker B, Karsten C, Meyer zu Schwabedissen HE, Seeland U, Böhm M, Bien S, Dazert P, Kunert-

Keil C, Vogelgesang S, Warzok R, Siegmund W, Cascorbi I, Wendt M, Kroemer HK. The Journal of Histochemistry and Cytochemistry. 2002; 50: 1-6.

**Bookchapters**

1. *Pharmakogenetik: Einfluss der Gene auf individuelle Wirkung der Medikamente* Leitfaden Personalisierte Medizin der Schweizerische Akademie der Medizinischen Wissenschaften. 2018.
2. *The role of pharmacogenomics within the concept of Individualized Medicine*. Individualized Medicine – ethical, economical and historical perspectives. Editors Langanke, Fischer, Marschall and Michl. 2015; 93-112. Springer Verlag, Heidelberg.
3. *Geschlechtsspezifische Unterschiede in der Behandlung kardiovaskulärer Erkrankungen.* Gender-Medizin Krankheit und Geschlecht in Zeiten der individualisierten Medizin. Editors Mariacarla Gadebusch Bondio and Elpiniki Katsari. 2014; 87-95. transcript Verlag.
4. *Pharmacogenetics of Drug Transporters in Pharmacogenetics and Individualized Therapy*. Editors Maitland-van der Zee & Daly. 2012; 101-48. John Wiley & Sons, Hoboken.
5. *In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2) in Drug Transporters.* Handbook of Experimental Pharmacology. Editors Fromm and Kim. 2011;(201):325-71. Springer Verlag, Heidelberg.